)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Annovis Bio (ANVS) investor relations material
Annovis Bio Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Focused on late-stage clinical development of buntanetap for Alzheimer's and Parkinson's diseases, with recent completion of key Phase 2/3 and Phase 3 trials and ongoing pivotal Phase 3 AD trial initiated in February 2025.
Achieved full activation of all 84 clinical sites for pivotal Phase 3 Alzheimer's study, with strong enrollment and first patients completing 6-month treatment milestone.
Published new pharmacokinetic data validating the novel crystalline form of buntanetap and secured global IP protection through 2046.
Announced significant biomarker reductions in neuroinflammation and neurodegeneration in Phase 2/3 AD trial, supporting disease-modifying potential.
No product revenue to date; operations funded primarily through equity offerings and warrant issuances.
Financial highlights
Net loss of $7.3 million for Q3 2025, an improvement from $12.6 million in Q3 2024; net loss of $19.0 million for the nine months ended September 30, 2025, compared to $18.7 million for the same period in 2024.
Research and development expenses rose to $6.3 million in Q3 2025, mainly due to increased costs for the AD 6-month trial; general and administrative expenses decreased to $1.1 million.
Cash and cash equivalents were $15.3 million as of September 30, 2025, up from $10.6 million at year-end 2024, excluding $9.4 million in October offerings.
Net loss per share improved to $0.37 for Q3 2025 from $0.97 in Q3 2024.
Operating cash burn for the nine months ended September 30, 2025 was $16.7 million.
Outlook and guidance
Current cash is expected to fund operations until Q3 2026, but additional capital will be required to support ongoing and future clinical development.
Progress toward symptomatic readout and NDA submission is on track, with all clinical and operational elements aligned.
Management plans to seek further funding through equity, debt, or other alternatives; failure to secure capital may require scaling back or ceasing operations.
How do biomarker findings inform Phase 3 AD?
What drives the Q3 2025 R&D expense increase?
What are the strategic benefits of new buntanetap form?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Annovis Bio earnings date
Q4 202527 Mar, 2026
Next Annovis Bio earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Annovis Bio Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and other central nervous system disorders. The company specializes in small molecule therapies designed to reduce neurotoxic proteins and improve brain function. The company is headquartered in Berwyn, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage